메뉴 건너뛰기




Volumn 5, Issue 1, 2013, Pages 68-79

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes

Author keywords

Dipeptidyl peptidase 4 inhibitor; Glycemic control; Incretins; Sitagliptin

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; PROINSULIN; ROSIGLITAZONE; SITAGLIPTIN;

EID: 84873465231     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00223.x     Document Type: Article
Times cited : (39)

References (36)
  • 1
    • 0000772523 scopus 로고    scopus 로고
    • Triple oral antidiabetic therapy in type 2 diabetes mellitus
    • Ovalle F, Bell DS. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998; 4: 146-7.
    • (1998) Endocr Pract , vol.4 , pp. 146-147
    • Ovalle, F.1    Bell, D.S.2
  • 2
    • 33745000699 scopus 로고    scopus 로고
    • Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients
    • Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care. 2006; 29: 554-9.
    • (2006) Diabetes Care , vol.29 , pp. 554-559
    • Rosenstock, J.1    Sugimoto, D.2    Strange, P.3    Stewart, J.A.4    Soltes-Rak, E.5    Dailey, G.6
  • 3
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB et al.Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 4
    • 79960796303 scopus 로고    scopus 로고
    • Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II)
    • Bell DS, Dharmalingam M, Kumar S, Sawakhande RB. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab. 2011; 13: 800-5.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 800-805
    • Bell, D.S.1    Dharmalingam, M.2    Kumar, S.3    Sawakhande, R.B.4
  • 5
    • 64749110344 scopus 로고    scopus 로고
    • Hypoglycemia: Still the limiting factor in the glycemic management of diabetes
    • Cryer PE. Hypoglycemia: Still the limiting factor in the glycemic management of diabetes. Endocr Pract. 2008; 14: 750-6.
    • (2008) Endocr Pract , vol.14 , pp. 750-756
    • Cryer, P.E.1
  • 6
    • 0041736553 scopus 로고    scopus 로고
    • Metformin: New understandings, new uses
    • Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs. 2003; 63: 1879-94.
    • (2003) Drugs , vol.63 , pp. 1879-1894
    • Hundal, R.S.1    Inzucchi, S.E.2
  • 7
    • 77957710722 scopus 로고    scopus 로고
    • Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents
    • Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs. 2010; 70: 1945-61.
    • (2010) Drugs , vol.70 , pp. 1945-1961
    • Derosa, G.1
  • 8
    • 79961222810 scopus 로고    scopus 로고
    • Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences
    • Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences. Drugs. 2011; 71: 1441-67.
    • (2011) Drugs , vol.71 , pp. 1441-1467
    • Baetta, R.1    Corsini, A.2
  • 9
    • 33749871472 scopus 로고    scopus 로고
    • Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    • Herman GA, Bergman A, Stevens C et al.Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91: 4612-9.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 4612-4619
    • Herman, G.A.1    Bergman, A.2    Stevens, C.3
  • 10
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131-57.
    • (2007) Gastroenterology , vol.132 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 11
    • 0035097211 scopus 로고    scopus 로고
    • Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects
    • Mannucci E, Ognibene A, Cremasco F et al.Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24: 489-94.
    • (2001) Diabetes Care , vol.24 , pp. 489-494
    • Mannucci, E.1    Ognibene, A.2    Cremasco, F.3
  • 12
    • 78449274342 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
    • Migoya EM, Bergeron R, Miller JL et al.Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010; 88: 801-8.
    • (2010) Clin Pharmacol Ther , vol.88 , pp. 801-808
    • Migoya, E.M.1    Bergeron, R.2    Miller, J.L.3
  • 13
    • 33845476757 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    • Sitagliptin Study 020 Group.
    • Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29: 2638-43.
    • (2006) Diabetes Care , vol.29 , pp. 2638-2643
    • Charbonnel, B.1    Karasik, A.2    Liu, J.3    Wu, M.4    Meininger, G.5
  • 14
    • 39749184723 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
    • Raz I, Chen Y, Wu M et al.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008; 24: 537-50.
    • (2008) Curr Med Res Opin , vol.24 , pp. 537-550
    • Raz, I.1    Chen, Y.2    Wu, M.3
  • 15
    • 34547660561 scopus 로고    scopus 로고
    • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
    • Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1979-87.
    • (2007) Diabetes Care , vol.30 , pp. 1979-1987
    • Goldstein, B.J.1    Feinglos, M.N.2    Lunceford, J.K.3    Johnson, J.4    Williams-Herman, D.E.5
  • 16
    • 23744434472 scopus 로고    scopus 로고
    • Rosiglitazone/metformin
    • Wellington K. Rosiglitazone/metformin. Drugs. 2005; 65: 1581-92.
    • (2005) Drugs , vol.65 , pp. 1581-1592
    • Wellington, K.1
  • 17
    • 34548316762 scopus 로고    scopus 로고
    • Pioglitazone and metformin
    • Hill NR, Matthews DR. Pioglitazone and metformin. Drugs Today. 2007; 43: 443-54.
    • (2007) Drugs Today , vol.43 , pp. 443-454
    • Hill, N.R.1    Matthews, D.R.2
  • 18
    • 33751557143 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • Sitagliptin Study 019 Group.
    • Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28: 1556-68.
    • (2006) Clin Ther , vol.28 , pp. 1556-1568
    • Rosenstock, J.1    Brazg, R.2    Andryuk, P.J.3    Lu, K.4    Stein, P.5
  • 19
    • 33845472504 scopus 로고    scopus 로고
    • Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    • Aschner P, Kipnes MS, Lunceford JK et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29: 2632-7.
    • (2006) Diabetes Care , vol.29 , pp. 2632-2637
    • Aschner, P.1    Kipnes, M.S.2    Lunceford, J.K.3
  • 20
    • 0021813187 scopus 로고
    • Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
    • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
    • (1985) Diabetologia , vol.28 , pp. 412-419
    • Matthews, D.R.1    Hosker, J.P.2    Rudenski, A.S.3    Naylor, B.A.4    Treacher, D.F.5    Turner, R.C.6
  • 21
    • 0034456568 scopus 로고    scopus 로고
    • Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans
    • Katz A, Nambi SS, Mather K et al.Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85: 2402-10.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2402-2410
    • Katz, A.1    Nambi, S.S.2    Mather, K.3
  • 22
    • 0026793272 scopus 로고
    • Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance
    • Yoneda H, Ikegami H, Yamamoto Y et al.Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care. 1992; 15: 1517-21.
    • (1992) Diabetes Care , vol.15 , pp. 1517-1521
    • Yoneda, H.1    Ikegami, H.2    Yamamoto, Y.3
  • 23
    • 0032580377 scopus 로고    scopus 로고
    • Interval estimation for the difference between independent proportions: Comparison of eleven methods
    • Newcombe RG. Interval estimation for the difference between independent proportions: Comparison of eleven methods. Stat Med. 1998; 17: 873-90.
    • (1998) Stat Med , vol.17 , pp. 873-890
    • Newcombe, R.G.1
  • 25
    • 28444440888 scopus 로고    scopus 로고
    • Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study
    • Bailey CJ, Bagdonas A, Rubes J et al.Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005; 27: 1548-61.
    • (2005) Clin Ther , vol.27 , pp. 1548-1561
    • Bailey, C.J.1    Bagdonas, A.2    Rubes, J.3
  • 26
    • 33749498694 scopus 로고    scopus 로고
    • Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    • Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006; 8: 650-60.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 650-660
    • Rosenstock, J.1    Rood, J.2    Cobitz, A.3    Biswas, N.4    Chou, H.5    Garber, A.6
  • 27
    • 69549135336 scopus 로고    scopus 로고
    • The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
    • DeFronzo RA, Hissa MN, Garber AJ et al.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32: 1649-55.
    • (2009) Diabetes Care , vol.32 , pp. 1649-1655
    • DeFronzo, R.A.1    Hissa, M.N.2    Garber, A.J.3
  • 28
    • 78751562877 scopus 로고    scopus 로고
    • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
    • Yoon KH, Shockey GR, Teng R et al.Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011; 65: 154-64.
    • (2011) Int J Clin Pract , vol.65 , pp. 154-164
    • Yoon, K.H.1    Shockey, G.R.2    Teng, R.3
  • 29
    • 77951069227 scopus 로고    scopus 로고
    • Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10246 patients with type 2 diabetes
    • Williams-Herman D, Engel SS, Round E et al.Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10246 patients with type 2 diabetes. BMC Endocr Disord. 2010; 10: 7.
    • (2010) BMC Endocr Disord , vol.10 , pp. 7
    • Williams-Herman, D.1    Engel, S.S.2    Round, E.3
  • 30
    • 34447267513 scopus 로고    scopus 로고
    • Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
    • Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298: 194-206.
    • (2007) JAMA , vol.298 , pp. 194-206
    • Amori, R.E.1    Lau, J.2    Pittas, A.G.3
  • 32
    • 34547161425 scopus 로고    scopus 로고
    • A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies
    • Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies. Curr Med Res Opin. 2007; 23: 1493-507.
    • (2007) Curr Med Res Opin , vol.23 , pp. 1493-1507
    • Barnett, A.1    Allsworth, J.2    Jameson, K.3    Mann, R.4
  • 33
    • 0036250329 scopus 로고    scopus 로고
    • Differentiating members of the thiazolidinedione class: A focus on safety
    • Lebovitz HE. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev. 2002; 18(Suppl. 2): S23-9.
    • (2002) Diabetes Metab Res Rev , vol.18 , Issue.SUPPL. 2
    • Lebovitz, H.E.1
  • 34
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 35
    • 54349120809 scopus 로고    scopus 로고
    • Cardiotoxic drugs: Clinical monitoring and decision making
    • Wu AH. Cardiotoxic drugs: Clinical monitoring and decision making. Heart. 2008; 94: 1503-9.
    • (2008) Heart , vol.94 , pp. 1503-1509
    • Wu, A.H.1
  • 36
    • 77957952617 scopus 로고    scopus 로고
    • Regulatory action on rosiglitazone by the U.S. Food and Drug Administration
    • Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med. 2010; 363: 1489-91.
    • (2010) N Engl J Med , vol.363 , pp. 1489-1491
    • Woodcock, J.1    Sharfstein, J.M.2    Hamburg, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.